Skip to the content
 
  • Payment Plans
  • Login for Professionals
  • English
    • Deutsch
    • Français
    • Italiano
    • English
  • Healthy Travelling
  • Countries
  • News
  • Special travellers
  • Health risks
  • Vaccinations
  • Ask a specialist

MENU

  • LogIn
  • English
    • Deutsch
    • Français
    • Italiano
    • English
  • Healthy Travelling
  • Countries
  • News
  • Special travellers
  • Health risks
  • Vaccinations
  • Ask a specialist
 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

Iraq

Latest News

According to Médecins Sans Frontières (MSF), 3,965 patients were treated for measles in Borno State in Nigeria from October to December 2023. The increase in the number of cases could be due to the fact that public health actors were unable to achieve the 95% vaccination rate due to the uncertain situation in the region. In addition, the interruption of routine childhood vaccinations during the COVID-19 pandemic contributed to the increase in cases.

On February 12, 2024, the Centres for Disease Control and Prevention (CDC) published the top 10 countries with measles outbreaks (data refer to the period July - December 2023):

  1. Yemen 18,464
  2. Azerbaijan 13,721
  3. Kazakhstan 13,195
  4. India 12,301
  5. Ethiopia 10,060
  6. Russian Federation 7,720
  7. Iraq 7,601
  8. Pakistan 7,027
  9. Kyrgyzstan 5,777
  10. Indonesia 3,205

Measles outbreaks are reported when the number of reported cases in an area is higher than the expected number of cases.

Checking measles protection should always be part of travel medical advice. All persons born after 1963 who do not have documented protection against the infection (antibodies or 2 documented vaccinations) should be vaccinated twice with MMR vaccine. In the event of an epidemic in the region or contact with a measles case, vaccination is recommended from the age of 6 months.
Via ProMED, 14.2.2024, CDC Feb 12 2024

General Information

  • Although the public health emergency of international concern for COVID-19 was declared over on 5 May 2023, COVID-19 remains a health threat
  • Adhere to the recommendations and regulations of your host country
  • Check entry requirements of destination country: see regulary updated COVID-19 Travel Regulations Map of IATA (LINK).

Vaccinations for all travellers

 
Risk Area
Factsheet
Flyer
SOP
MAP
Bookmark
Countrywide
 
 
Hepatitis A - Map
 

 
Recommendation
  • Hepatitis A vaccination is recommended for all travellers going to tropical or subtropical countries.
 

  • Hepatitis A is a liver infection caused by a virus.
  • The virus is easily transmitted through contaminated food or water, but can also be transmitted through sexual contact.       
  • There is a safe and very effective vaccine that offers lifelong protection.
  • The hepatitis A vaccination is recommended for all travellers to tropical or subtropical countries and for risk groups.

HEPATITIS A__ECTM_Factsheet_Layperson_EN.pdf

CDC Map: Estimated age of midpoint of population immunity (AMPI) to hepatitis A, by country
  • Hepatitis A is a liver infection caused by a virus.
  • The virus is easily transmitted by contaminated food or water but can also be transmitted through sexual contact.
  • A safe and very effective vaccine is available that affords long-lasting protection.
  • Hepatitis A vaccination is recommended for all travelers going to tropical or subtropical countries, and for risk groups.
Hepatitis A is caused by a highly contagious virus that affects the liver. It is also known as infectious jaundice or traveller's hepatitis. Hepatitis A is one of the most common infectious diseases that can be contracted when travelling if you have not been vaccinated against it.

Hepatitis A occurs worldwide, but the risk of infection is higher in countries with poor hygiene conditions. There is an increased risk in most tropical and subtropical countries as well as in some countries in Eastern Europe and around the Mediterranean. Outbreaks in northern European countries can also occur when unvaccinated children become infected during family visits to tropical and subtropical countries and transmit the virus in their care facilities on their return.

In recent years, there has also been an increase in cases in North America and Europe, including Switzerland, particularly among men who have sex with men (MSM).

 

Transmission mainly occurs through contaminated (faecal) drinking water or food. Other transmission routes are close personal contact, especially sexual contact (anal-oral sex) or inadequate hand hygiene.
Around 2-4 weeks after infection, symptoms such as fever, tiredness, nausea, loss of appetite and diarrhoea may occur. Yellow skin and eyes (jaundice) may follow within a few days. Most symptoms disappear after a few weeks to months, although fatigue can persist for months. In young children, there are usually few or no symptoms, but in older people, the disease can be severe and protracted. Once the infection has been cured, immunity is lifelong.
There is no specific treatment. Recovery from an acute hepatitis A infection can take several weeks to months. Vaccination up to 7 days after contact with the virus can prevent the outbreak or mitigate the course of the disease.

There is a safe and very effective vaccine that consists of two injections at least 6 months apart. It offers lifelong protection after the second dose. The hepatitis A vaccination can also be administered in combination with the hepatitis B vaccination (3 doses required if given to persons 16 years and older).

Vaccination against hepatitis A is recommended for all travellers to risk areas and for people with an increased personal risk, such as people with chronic liver disease, men who have sex with men and people with an increased occupational risk, such as in the health service or in contact with waste water.

 

  • Federal Office of Public Health (FOPH). Hepatitis A
  • Hepatitis Switzerland
     
See map
 
 
 
 

 
Recommendation

In addition to the basic immunisation against polio, a booster vaccination is recommended for

  • immunocompetent travellers <65 years: every 20 years
  • immunocompetent travellers ≥65 years: every 10 years
  • travellers with immunodeficiency: every 10 years
 

 
Country requirement at entry
  • Passengers arriving at Erbil (EBL) from Afghanistan, Nigeria, Pakistan, Somalia, South Sudan or Syria, are recommended to hold an International Certificate of Vaccination proving the passenger was vaccinated against polio. Those not holding a Certificate of Vaccination will receive a dose of oral polio vaccine (OPV) on arrival.
  • Passengers arriving at Bagdhdad (BGW) and Najaf (NJF) from Afghanistan, Algeria, Angola, Benin, Botswana, Burkina Faso, Cameroon, Canada, Central African Rep., Chad, Congo, Congo (Dem. Rep.), Cote d’Ivoire, Djibouti, Egypt, Eritrea, Gambia, Ghana, Guinea, Indonesia, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Nigeria, Pakistan, Palestinian Territory, Senegal, Sierra Leone, Somalia, South Africa, Sudan, Syria, Tanzania, Uganda, Ukraine, Yemen, Zambia or Zimbabwe, are recommended to hold an International Certificate of Vaccination proving the passenger was vaccinated against polio at least 14 days before arrival. Those not holding a Certificate of Vaccination will receive a dose of oral polio vaccine (OPV) on arrival.

 

 

 

  • Polio is a vaccine-preventable viral disease of the nervous system that is acquired mainly through the consumption of food or water contaminated by feces.
  • The infection with the poliovirus can affect children and adults and may lead to permanent limb or respiratory muscle paralysis and death.
  • An effective, well-tolerated vaccine is available! Check if booster doses are recommended (on top of completed basic vaccination schedule).

EKRM_Factsheet_Layperson_EN_Polio.pdf

In addition to the basic immunisation against polio, a booster vaccination is recommended for

  • immunocompetent travellers <65 years: every 20 years
  • immunocompetent travellers ≥65 years: every 10 years
  • travellers with immunodeficiency: every 10 years
  • Passengers arriving at Erbil (EBL) from Afghanistan, Nigeria, Pakistan, Somalia, South Sudan or Syria, are recommended to hold an International Certificate of Vaccination proving the passenger was vaccinated against polio. Those not holding a Certificate of Vaccination will receive a dose of oral polio vaccine (OPV) on arrival.
  • Passengers arriving at Bagdhdad (BGW) and Najaf (NJF) from Afghanistan, Algeria, Angola, Benin, Botswana, Burkina Faso, Cameroon, Canada, Central African Rep., Chad, Congo, Congo (Dem. Rep.), Cote d’Ivoire, Djibouti, Egypt, Eritrea, Gambia, Ghana, Guinea, Indonesia, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Nigeria, Pakistan, Palestinian Territory, Senegal, Sierra Leone, Somalia, South Africa, Sudan, Syria, Tanzania, Uganda, Ukraine, Yemen, Zambia or Zimbabwe, are recommended to hold an International Certificate of Vaccination proving the passenger was vaccinated against polio at least 14 days before arrival. Those not holding a Certificate of Vaccination will receive a dose of oral polio vaccine (OPV) on arrival.

 

 

EKRM_Factsheet_Layperson_EN_Polio.pdf

  • Polio is a vaccine-preventable viral disease of the nervous system that is acquired mainly through the consumption of food or water contaminated by feces.
  • The infection with the polio virus can affect children and adults and may lead to permanent limb or respiratory muscle paralysis and death.
  • An effective, well- tolerated vaccine is available! Check if booster doses are recommended for the travel destination (on top of completed basic vaccination schedule).
Poliomyelitis, or polio, is a highly infectious viral disease that affects the nervous system and can cause total limb paralysis within a very short time period. People of all ages can be infected through consumption of contaminated food or water. Humans are the only known reservoir of the polio virus.  Infection may be mild or even without symptoms. If symptoms of muscular or nervous system complications appear, sequelae (long-term complications) almost always occur. There is no medication to cure polio but the vaccine against polio is highly efficacious.
Polio due to wild types of viruses has been eradicated from most countries. In Afghanistan and Pakistan, however, new infections still occur. In some countries, polio viruses derived from live, oral vaccines are circulating and cause outbreaks of polio disease, especially in countries where vaccination coverage against polio is low in the population.
Polio virus is mainly transmitted through the consumption of food or water contaminated by feces. The virus can also be acquired through secretions or saliva of an infected person. In the tropics, transmission occurs year round, whereas in temperate zones, a peak can be seen in summer.
Symptoms most commonly appear 3 to 21 days following exposure. Initial symptoms may include fever, fatigue, headache, vomiting, and diarrhea. Those with mild cases may recover within a week. More serious cases result in stiffness of the neck and pain in the limbs. 1 in 200 infections leads to irreversible limb or respiratory muscle paralysis.
There is no cure for polio. Treatment targets symptom alleviation only.

Regular hand washing after using the bathroom and before eating or preparing food. Avoidance of undercooked or raw food that is potentially contaminated with fecal material.

The most important prevention is vaccination. A very effective and well-tolerated vaccine against polio is available (inactivated (killed) polio vaccine (IPV)), which is part of the basic vaccination schedule during childhood. Combination vaccines (e.g. with diphtheria and tetanus) are also available. After basic vaccination, a booster dose is recommended every 10 years for travel to certain countries (see country page recommendations). WHO recommends a yearly vaccination for residents or long-stay visitors (minimum 4 weeks) in a country with ongoing polio infections or circulating vaccine-derived polio viruses. This recommendation not only targets individual protection, but aims to prevent the international spread of the virus.

Check the risk for polio in the region of travel, and ensure vaccination if recommended (see country page recommendations).
  • WHO: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis
  • FOPH Switzerland: Swiss vaccination plan: https://www.bag.admin.ch/bag/de/home/gesund-leben/gesundheitsfoerderung-und-praevention/impfungen-prophylaxe/schweizerischer-impfplan.html
Worldwide
  
 
 
 
 

 
Recommendation

All travellers should have completed a basic immunisation and boosters according to the Swiss vaccination schedule, LINK.

 

Worldwide
 
 
 
 

 
Recommendation

All travellers should have completed a basic immunisation and boosters according to the Swiss vaccination schedule, LINK.

 

General information on measles, mumps and rubella (MMR)

Please consult the following FOPH links:

  • Measles
  • Mumps
  • Rubella

MMR_ECTM_Factsheet_layperson_EN.pdf

Worldwide
 
 
 
 

 
Recommendation

Travellers should be immune to chickenpox. Persons between 13 months and 39 years of age who have not had chickenpox and who have not received 2 doses of chickenpox vaccine should receive a booster vaccination (2 doses with minimum interval of 4 weeks), see Swiss vaccination schedule, LINK.

 

Please consult the following link of the FOPH:

 

General information about chickenpox (varicella) and shingles (herpes zoster)

  • Link to the document 

CHICKENPOX_SHINGLES_ECTM_Factsheet_Layperson_EN.pdf

Vaccinations for some travellers

 
Risk Area
Factsheet
Flyer
SOP
MAP
Bookmark
 
 
 

 
WHO recommendation
For medical reasons: vaccination is not recommended..
 

 
Country requirement at entry

For administrative reasons, there is the following entry regulation of the country:

  • Vaccination is required if arriving within 6 days after leaving or transiting countries with risk of yellow fever transmission.

Exempt from this entry requirement:

  • Children under 6 months of age.
  • Passengers transiting Iraq if not leaving the transit area.
  • Passengers transiting countries with risk of yellow fever transmission if not leaving the transit areas.
 

  • Yellow fever is a life-threatening viral infection. A highly effective vaccine is available. 
  • Vaccination is strongly recommended for all travellers to regions where yellow fever occurs, even if it is not a mandatory entry requirement of the country.
  • A booster single booster dose is recommended for immuncompetent persons after 10 years.
  • The yellow fever vaccination must be administered by an authorized doctor or center at least ten days before your arrival in the destination country with record in the yellow vaccination booklet ('International Certificate for Vaccination').
  • For travellers who are pregnant, breastfeeding, or who have a condition that leads to immunosuppression, please consult a travel health advisor.

EKRM_Factsheet_Layperson_EN_Yellow-fever.pdf

EKRM_Factsheet_Layperson_EN_Mosquito-and-tick-bite-protection.pdf

For medical reasons: vaccination is not recommended..

For administrative reasons, there is the following entry regulation of the country:

  • Vaccination is required if arriving within 6 days after leaving or transiting countries with risk of yellow fever transmission.

Exempt from this entry requirement:

  • Children under 6 months of age.
  • Passengers transiting Iraq if not leaving the transit area.
  • Passengers transiting countries with risk of yellow fever transmission if not leaving the transit areas.

ETCM Map: Yellow fever vaccination recommendation in Africa

 

Yellow_fever_vaccination_map_AFRICA.jpg

CDC Map: Yellow fever vaccine recommendations for the Americas

 

Footnotes

  • Current as of November 2022. This map is an updated version of the 2010 map created by the Informal WHO Working Group on the Geographic Risk of Yellow Fever.
  • In 2017, the Centers for Disease Control and Prevention (CDC) expanded its yellow fever vaccine recommendations for travelers going to Brazil because of a large outbreak in multiple states in that country. For more information and updated recommendations, refer to the CDC Travelers’ Health website.
  • Yellow fever (YF) vaccination is generally not recommended for travel to areas where the potential for YF virus exposure is low. Vaccination might be considered, however, for a small subset of travelers going to these areas who are at increased risk for exposure to YF virus due to prolonged travel, heavy exposure to mosquitoes, or inability to avoid mosquito bites. Factors to consider when deciding whether to vaccinate a traveler include destination-specific and travel-associated risks for YF virus infection; individual, underlying risk factors for having a serious YF vaccine-associated adverse event; and country entry requirements.
  • Yellow fever occurs in sub-Saharan Africa and South America and is transmitted by mosquitoes.
  • Disease may be severe in unvaccinated travelers and death may occur in over 50%.
  • A highly effective vaccine is available.
  • Due to potentially severe side effects the vaccine is used with caution in immunocompromised or elderly individuals, as well as in pregnant women.
Yellow fever is an acute viral infection transmitted through the bite of mosquitoes. The disease occurs in sub-Saharan Africa and South America. It is a potentially lethal disease. However, the vaccination offers very high protection.
Yellow fever is endemic in countries of sub-Saharan Africa and South America, and in Panama. Transmission occurs all over the year but may peak in the rainy season. Although the same species of mosquitoes are present, yellow fever has not been found in Asia.
The yellow fever virus is transmitted to people primarily through the bite of infected daily active Aedes mosquitoes, or Haemagogus species mosquitoes, which are day and night active. Mosquitoes acquire the virus by feeding on infected primates (human or non-human) and then can transmit the virus to other primates (human or non-human). Yellow fever transmission and epidemics are facilitated by the interface of jungle, savannah and urban areas. Humans working in the jungle can acquire the virus and become ill. The virus then can be brought to urban settings by infected individuals and may be transmitted to other people.
Most people infected with yellow fever virus have mild or no symptoms and recover completely. Some people will develop yellow fever illness with onset of symptoms typically 3 to 6 days after infection. Symptoms are unspecific and flu-like (fever, chills, head and body pain). After a brief remission, about 10-20% will develop more severe disease. Severe disease is characterized by high fever, yellow skin and eyes, bleeding, shock and organ failure. About 30 to 60% of patients with severe disease die.
There is no specific medication. Treatment is only supportive and consists of providing fluid and lowering fever. Aspirin and other nonsteroidal anti-inflammatory drugs, for example ibuprofen or naproxen, should be avoided due to the risk of enhanced bleeding.

As against all mosquito-borne diseases, prevention from mosquito bites is during day and night (see “Insect and tick bite protection” factsheet). The available vaccine is highly efficacious and provides a long-term protection. It is recommended for people aged 9 months or older who are travelling to yellow fever endemic areas. In addition, providing proof of vaccination may be mandatory for entry into certain countries.

The vaccine is a live-attenuated form of the virus. In immunocompetent persons, protection starts about 10 days after the first vaccination. Reactions to yellow fever vaccine are generally mild and include headache, muscle aches, and low-grade fevers.  Side effects can be treated with paracetamol but aspirin and other nonsteroidal anti-inflammatory drugs, for example ibuprofen or naproxen, should be avoided.  On extremely rare occasions, people may develop severe, sometimes life-threatening reactions to the yellow fever vaccine – which is why this vaccine is used with caution in immunocompromised individuals, pregnant women and the elderly for safety reasons. Talk to your travel health advisor if you belong to this group.

In 2016, WHO changed from yellow fever booster doses every 10 years to a single dose, which is considered to confer life-long protection. However, this decision was based on limited data and mainly from endemic populations, potentially exposed to natural boosters (through contact with infected mosquitoes), which does not apply to travellers from non-endemic regions. As several experts have raised concerns about the WHO single dose strategy, the Swiss Expert Committee for Travel Medicine recommends a single booster dose ≥10 years (max. 2 doses per life-time) in immunocompetent persons after primo-vaccination before considering life-long immunity.
Yellow Fever Map - Centers for Disease Control and Prevention: https://www.cdc.gov/yellowfever/maps/index.html 
Yellow Fever Info - Centers for Disease Control and Prevention: https://www.cdc.gov/yellowfever/index.html 
Yellow Fever Info - European Centre for Disease Prevention and Control: https://www.ecdc.europa.eu/en/yellow-fever/facts 
Countrywide
  
 
 
 
  • Typhoid fever is a serious disease that is caused by bacteria and transmitted through contaminated food or water.
  • The risk is very low for travellers who have access to safe food and drinks.
  • The best protection against typhoid fever is to follow optimal basic hygiene.
  • A vaccination against typhoid is available that is recommended in following circumstances
    • Visit to an area with poor hygienic conditions (e.g. travelling to rural areas)
    • Short stay (>1 week) in a high-risk (hyper-endemic) country (see country page)
    • Long-term stays (> 4 weeks) in an endemic country
    • Presence of individual risk factors or pre-existing health conditions. In that case, please talk to your health advisor.
  • Typhoid fever, also called enteric fever, is caused by the bacteria Salmonella Typhi and Salmonella Paratyphi.
  • Infected persons shed the bacteria in their feces. In countries with low sanitation standards, the bacteria can then enter the drinking water system and lead to infections in other people.
  • Frequent sources of infection are contaminated food and beverages.
  • The main preventive measure therefore is “cook it, peel it, boil it or forget it” – meaning: avoid drinking uncooked water or water from unsealed bottles; avoid cooled/frozen products (e.g. ice cubes in drinks, ice cream) unless from a known safe source; avoid uncooked vegetables, peel and clean fruit and vegetables yourself and only with known safe drinking water.
  • A vaccine is available and recommended: a) for travelers to the Indian subcontinent or to West Africa, b) for travelers visiting friends and relatives or for long-term travelers also to other sub-/tropical areas.
Typhoid fever is a bacterial disease that affects the whole body and mainly presents with high fever, often accompanied by drowsiness (“typhos” in Greek stands for delirium) and severe headaches. If the infection is treated with appropriate antibiotics, mortality is very low. If left untreated however, complications may follow, which can lead to significant mortality. Typhoid fever must be clearly distinguished from salmonellosis, caused by a large range of non-typhoidal salmonella species that mainly cause benign diarrheal symptoms worldwide.
The highest occurrence of typhoid fever is on the Indian subcontinent (Afghanistan, Pakistan, Nepal, Bhutan, India and Bangladesh). This is also the region with a steady increase in antibiotic resistance. The disease also occurs in the whole sub-/tropical region, but with lower frequency. It used to occur also in Europe and North America, but the disease has disappeared thanks to improved water and sanitation standards.
Typhoid fever is transmitted via the fecal-oral route: bacteria are shed in the feces of infected persons and – if insufficient hand hygiene is practiced – infected persons may contaminate the food and drinking water supply of their families. In regions with low sanitation standards, contaminated feces may also contaminate the public drinking water supply.
The incubation period – time between infection and first symptoms – can vary between 3 days to 3 weeks. The principle symptom of typhoid fever is high-grade fever (39° - 41° C) accompanied by strong headache and drowsiness. In the initial phase of the disease, patients often complain of constipation. In later stages, this may turn into diarrhea. In later stages of the disease - and in the absence of correct treatment - complications such as septicemia, intestinal hemorrhage or perforation can follow, which may lead to considerable mortality.
Appropriate antibiotic treatment cures typhoid fever. Treatment should be adapted according to the resistance profile of the bacteria. On the Indian subcontinent, some strains may be multi-resistant, necessitating broad-spectrum intravenous antibiotic treatment. In severe typhoid fever with reduced consciousness (delirium) or coma, treatment with corticosteroids may need to be added.

“Cook it, boil it, peel it or forget it” – this simple slogan would be sufficient to prevent typhoid fever nearly entirely. However, only few travelers fully adhere to this advice. Nevertheless, the value of food and water hygiene cannot be stressed enough: avoid buying water bottles without proper sealing, avoid drinking tap water from unknown sources, avoid eating cooled / frozen foods (i.e. ice cubes in water or ice cream) and avoid eating raw fruits and vegetables that you yourself have not peeled and washed with clean drinking water.

Two types of vaccines are available:

  • Oral (live) vaccine consisting of three capsules to be taken on alternate days on empty stomach. These capsules require refrigeration before use. Protection from this vaccine is approximately 70% and starts 10 days after the third dose. After 1 to 3 years, the vaccine needs to be taken again before a new travel into at-risk areas. This vaccine cannot be given to patients with a severe chronic gastrointestinal disease (such as Crohn’s disease or ulcerative colitis) or with severe immunosuppression.
  • The single-dose vaccine is an inactivated vaccine and is injected intramuscularly. Protection also reaches around 70% and starts 14 days after the injection. This vaccine can be given to patients who should not take the oral vaccine. However, it is not registered in Switzerland, but most doctors with specialization in tropical and travel medicine and all travel health centres have the vaccine on stock. Duration of protection is around 3 years.
Vaccination against typhoid fever is advised for long-term travelers and for travelers visiting areas where the risk of transmission is particularly high and/or the disease more difficult to treat due to severe antibiotic resistance.
Federal Office of Public Health Switzerland: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/typhus-abdominalis-paratyphus.html 
Countrywide
 
 
 
  • Rabies is mainly transmitted by dogs (and bats), but any mammal can be infectious.
  • The disease is invariably fatal at the time when symptoms occur.
  • Rabies is best prevented by a pre-travel vaccination and appropriate behavior towards mammals (avoiding contacts).
  • Pre-travel vaccination (see section prevention) is also recommended because vaccines and immunoglobulins are often not available in many travel countries.  
  • Attention: a bite or a scratch wound as well as a contact with mammal saliva on an open wound is always an emergency! Find out about the necessary actions below!

RABIES_ECTM_Factsheet_Layperson_EN.pdf

This fact sheet contains important information about rabies. For optimal travel preparation, we recommend that you read this information carefully and take the fact sheet on your trip!
  • Rabies is mainly transmitted by dogs (and bats), but any mammal can be infectious.
  • The disease is invariably fatal at the time when symptoms occur.
  • Rabies is best prevented by a pre-travel vaccination and appropriate behavior towards mammals (avoiding contacts).
  • Pre-travel vaccination (see section prevention) is also recommended because vaccines and immunoglobulins are often not available in many travel countries.  
  • Attention: a bite or a scratch wound as well as a contact with mammal saliva on an open wound is always an emergency! Find out about the necessary actions below!
Rabies disease is invariably fatal, transmitted through the saliva or other body fluids of infected mammals.
Dogs are responsible for more than 95 % of human cases. Bats, cats, (rarely) monkeys, and any other mammals can transmit rabies! The highest risk areas are Asia, Africa and some Latin American countries (e.g. Bolivia). Rabies may occur anywhere in the world except in countries where successful eradication has been achieved.
Saliva from infected animals enters the human body through injured skin, either via bites and scratches or by licking already wounded skin. Once it has entered the body through the skin lesion, the rabies virus migrates along nerve pathways towards the brain. In most cases, this migration takes several weeks to months and proceeds without accompanying symptoms.
Symptoms usually only appear when the virus has reached the brain. In most cases, this is the case after 2-12 weeks
(range: 4 days - several years!) and manifests itself as encephalitis (inflammation of the brain), which in 99.99% of cases is fatal within a few weeks. As soon as symptoms of encephalitis appear, a fatal course can no longer be prevented.

No treatment against rabies disease exists!

 

Post-exposure measures: clean the wound immediately with plenty of water and soap for 10-15 minutes, then disinfect the wound (e.g. Betadine®, Merfen®), and immediately (i.e. during the trip!) get emergency post-exposure vaccination against rabies: for those having received full pre-exposure rabies vaccination before travel, two additional vaccine shots (any available brand) at an interval of 3 days suffice and should be administered as soon as possible on site (i.e. also while travelling). If full pre-exposure vaccination has not been given, in addition to vaccination, passive immunization is required with immunoglobulins within the shortest delay on site.

Of note, immunoglobins (and sometimes vaccines) are often unavailable in low-resource settings, causing stress and uncertainty. Tetanus booster vaccination may be also warranted.

Petting any mammals while travelling is not a good idea, even if they are cute! Do not feed them! Refrain from touching wild or unfamiliar or dead animals. 

Vaccination against rabies (preexposure vaccination) is highly recommended for:

  • Repeated travels or long-term stay in endemic countries.
  • Short journeys with high individual risk, especially for travellers on ‘two wheels’ or treks in remote areas, toddlers and children.
  • Persons, working with animals, or cave explorers (bats!).

The shortened vaccination schedule can be proposed to most travellers: 2 doses given at least 7 days apart before departure. A single lifetime booster dose (3rd dose) is recommended after one year or later when further travelling to rabies endemic countries is undertaken. If you have an immune deficiency, please consult your doctor, as different vaccination intervals apply to you.

  • In case of trips planned, schedule a visit at the travel clinic 4 weeks before departure at the latest. But if it's really urgent, an appointment 10 days before departure will suffice.
  • After exposure (bite, scratch injury): seek medical attention immediately (meaning even during travel!) to get wound treatment and postexposure vaccinations against rabies! This is also necessary even for those with a completed series of basic vaccinations before travel!
  • This information leaflet should be printed and kept handy during the trip!
  • FOPH Switzerland (German): LINK
Worldwide
 
 
 
  • Hepatitis B is a liver infection caused by a virus.
  • The virus is transmitted through sexual contact, but can also be transmitted through blood (products), e.g. when sharing syringes, tattoo needles, etc.
  • There is a safe and very effective vaccine that offers long-lasting protection.
  • The hepatitis B vaccination is recommended for all infants and adolescents up to the age of 16 and for risk groups regardless of age.

    HEPATITIS-B_ECTM_Factsheet_Layperson_EN.pdf

    Worldwide
     
     
     

     
    Recommendation

    Vaccination recommendation according to the Swiss Federal Office of Public Health (BAG), see LINK.

    Entry requirement per country, see IATA LINK.

     

    • Covid-19 is a disease that affects the whole body, but mainly shows with respiratory symptoms such as cough and difficulty in breathing. It is caused by the SARS-CoV-2 virus.
    • The infection is mainly spread through respiratory droplets and possibly aerosols when infected persons cough, sneeze, speak or sing without wearing a mask.
    • The infection can be prevented very effectively by vaccination and an increasing number of vaccines are now approved and available for protection.
    • Vaccination is recommended according to the Swiss recommendations of the Federal Office of Public Health (FOPH), see LINK.
    • Furthermore, prevention relies heavily on people wearing face masks, on hand hygiene and on physical distancing (min. 1.5 m) if masks are not worn and people are not vaccinated.

    COVID19_ECTM_Factsheet_Layperson_EN.pdf

    For information, see LINK of the Federal Office of Public Health (FOPH)
    Countrywide
      
     
     
     
    • Influenza is common all over the world including sub-tropical and tropical countries.
    • Vaccination offers the best protection. 
    • Vaccination against flu is recommended for all travellers who belong to an “at risk” group such as pregnant travellers, travellers with comorbidities, elderly people (>65 years), or who plan a a high-risk trip (e.g. cruise-ship, pilgrimage).
    • The influenza vaccine does not offer protection against avian flu.

    INFLUENZA_ECTM_Factsheet_EN.pdf

    General informations about seasonal flu (influenza)

    Please consult the following FOPH links:

    • Seasonal flu (influenza)
     

    Malaria

     
    Risk Area
    Factsheet
    Flyer
    Infosheet
    MAP
    Bookmark
     
     
    Malaria - Worldmap
     

     
    Note
    No autochthonous cases reported since 2009. Due to the political situation / possibly limited surveillance, sporadic cases are possible.
     

     
    Low risk
    • From May to November: <1500m in the northeast.
       

    Prevention: Mosquito bite prevention.

     

    • Malaria is a life-threatening parasitic infection, which is transmitted by mosquitoes at night.
    • Great care should be given to preventive mosquito protection from dusk to dawn in all malaria risk areas.
    • In high-risk areas, taking regular prophylactic medication is strongly advised.
    • For stays in low risk areas: discuss with a travel health advisor whether carrying stand-by emergency self-treatment against malaria is recommended.
    • If you belong to a special risk group (pregnant women, small children, senior citizens, persons with pre-existing conditions and/or with immune deficiency): seek medical advice before the trip as malaria can quickly become very severe.
    • If you have a fever >37.5°C on measuring under your arm or in your ear (a functioning thermometer is indispensable!) during or after the trip, see a doctor / hospital immediately and have a blood test done for malaria! This applies regardless of whether you used prophylactic medication or not!
    • For personal safety, we strongly recommend getting informed in detail about malaria and reading the following information.

      EKRM_Factsheet_Layperson_EN_Malaria.pdf

      EKRM_Factsheet_Layperson_EN_Mosquito-and-tick-bite-protection.pdf

      No autochthonous cases reported since 2009. Due to the political situation / possibly limited surveillance, sporadic cases are possible.
      • From May to November: <1500m in the northeast.
         

      Prevention: Mosquito bite prevention.

      2024-09-21_EKRM_World_Malaria_Map_2024_(c)_EN.jpg

      For personal safety, we strongly recommend getting informed in detail about malaria and taking this factsheet with you on your trip.
      • Malaria is a life-threatening parasitic infection, which is transmitted by mosquitoes at night.
      • Great care should be given to preventive mosquito protection from dusk to dawn in all malaria risk areas.
      • In high-risk areas, the intake of prophylactic medication is strongly advised.
      • For stays in low risk areas: discuss with a travel health advisor whether carrying an emergency self-treatment against malaria is necessary.
      • If you belong to a special risk group (pregnant women, small children, senior citizens, persons with pre-existing conditions and/or with immune deficiency): seek medical advice before the trip as malaria can quickly become very severe.
      • If you have a fever >37.5°C on axillary or tympanic measurement (a functioning thermometer is indispensable!) during or after the trip, see a doctor / hospital immediately and have a blood test done for malaria! This applies regardless of whether you have used prophylactic medication or not!
      Malaria is a life-threatening acute febrile illness caused by parasites called Plasmodia, which are transmitted by mosquitoes at night (between dusk and dawn). Rapid diagnosis and treatment are crucial to prevent complications and death, and to cure the disease. To prevent malaria, diligent mosquito-bite protection is important, as well as taking additional prophylactic (preventive) medication when staying in high-risk areas. Risk groups such as pregnant women, small children, elderly persons or travellers with complex chronic conditions should seek specialized advice.
      Malaria occurs widely in tropical and subtropical areas of Africa, Asia, South and Central America (see also malaria map).
      Plasmodia are transmitted to humans by Anopheles mosquitoes, which only bite between dusk and dawn. They sometimes go unnoticed, because they are small and make almost no noise.
      After visiting a malaria endemic area, the symptoms usually appear seven days to one month after infection, but sometimes after several months or more than a year. Symptoms begin with fever and may appear very similar to flu. Other symptoms may include headache, muscle pain, nausea, and sometimes diarrhea or cough. The diagnosis can only be confirmed with a blood test.

      Fever during or after a stay in a malaria-endemic area is an emergency! Prompt diagnosis and treatment are required as the health of people with malaria can deteriorate very quickly. That means: if you have fever >37.5° (use a thermometer!) you need to test for malaria within a maximum time-frame of 24 hours, regardless of whether or not you have used prophylactic medication (malaria chemoprophylaxis). Try to reach a doctor or hospital where you can reliably receive such a test. If the first test is negative, it should be repeated on the following day if the fever persists.

      Malaria can be treated effectively, but without treatment, this disease can quickly cause complications and become fatal. People who have had malaria in the past are not protected from being infected again.

      Prevention of malaria requires a combination of approaches:

      1. Diligent mosquito-bite protection at dusk and at night until dawn is of key importance. Use it for all regions where malaria is present, including areas where the risk is minimal. Bite protection is also effective against other insect-borne diseases that often occur in the same region. It consists of the following measures:
        • Clothing: Wear long-sleeved clothes and long trousers. For additional protection, impregnate the clothes beforehand with insecticides containing the active ingredient permethrin (e.g. Nobite® Textile).
        • Mosquito repellents: Apply a mosquito repellent to uncovered skin.
        • Sleeping room: Sleep in an air-conditioned room or under an impregnated mosquito net. Cautiously use ‘knockdown’ sprays indoors or burn mosquito coils strictly outside, e.g. under a table in the evening.
        • Chemoprophylaxis: Depending on the region and season, it may be necessary to take a prophylactic medication. This is recommended for all destinations with a high risk of malaria (marked as red on our maps). It needs to be taken with food before, during, and after your stay. Discuss with your travel health advisor to ascertain if you need to take chemoprophylaxis for your trip. The appropriate medication and the right dosage will be prescribed.
      2. Taking standby emergency self-treatment (SBET, drugs used to self-treat malaria) with you is recommended for special risk situations (stay in regions with low malaria risk and if there is no or uncertain medical care available). Following such a course of SBET, please consult a doctor as soon as possible. Talk to your travel health advisor to determine whether carrying SBET is necessary, especially if you plan a trip where reliable medical infrastructure is not assured.
      3. For some risk groups, malaria can quickly develop to a dangerous disease. If you are pregnant, if you are travelling with small children, or if you are a senior citizen and / or if you have other illnesses /pre-existing conditions and / or you are immunocompromised, you should seek advice from a specialist in travel medicine to determine whether chemoprophylaxis is recommended for your trip – even if the area is marked as low risk malaria zone.

      For travellers, there is currently no malaria vaccination available.

      • Take a functioning clinical thermometer with you!
      • Malaria symptoms develop at the earliest 7 days after entering the malaria area. A fever > 37.5° always means suspicion of malaria!
      • In case you have fever during or even months after a stay in a malaria area:
        • Immediately consult a health care facility to rule out malaria through a blood test.
        • This should be done within a maximum of 24 hours and applies regardless of whether you have used prophylactic medication or not!
        • The blood tests should be repeated if the result is negative or doubtful and fever persists or recurs.
      • For persons having visited a malaria area with low risk and for whom SBET was prescribed:
        • If you have fever: immediately try to get tested for malaria.
        • If this is not possible, and fever persists for longer than 24 hours or recurs: start taking the standby emergency-self-treatment as it was prescribed by your travel health advisor.
        • Even if you have started your self-treatment against malaria: seek medical advice as quickly as possible to get the cause of your fever diagnosed.

      Other health risks

       
      Risk Area
      Factsheet
      Flyer
      Infosheet
      MAP
      Bookmark
      Worldwide
       
       
       
      • Sexually transmitted infections (STIs) are a group of viral, bacterial and parasitic infections; while many are treatable, some can lead to complications, serious illness or chronic infection.
      • STIs are increasing worldwide.
      • Read the following fact sheet for more information.

      EKRM_Factsheet_Layperson_DE_STI.pdf

      EKRM_Factsheet_Layperson_DE_HIV-AIDS.pdf

      • Geschlechtskrankheiten sind ein weltweit verbreitetes Gesundheitsproblem und können durch Prävention, regelmässiges Testen und Behandlung in den Griff bekommen werden.
      • Das Wissen um Risiken sowie Safer-Sex-Praktiken inklusive Kondomgebrauch sind wichtig. Falls Sie mehr dazu erfahren wollen, wie Sie sich während der Reise optimal schützen können, besprechen Sie dies mit einer Fachperson.
      • Hatten Sie eine Risikosituation, ist es wichtig mit einer Fachperson so rasch wie möglich Rücksprache zu halten, um zu erörtern, ob eine HIV-Post-Expositions-Prophylaxe (PEP) durchgeführt werden soll, um eine Ansteckung mit HIV zu verhindern.
      • Im Nachgang einer Risikosituation ist es wichtig sich auf Geschlechtskrankheiten testen zu lassen. Auch dann, wenn Sie keine Symptome haben.
      Reisende, die Gelegenheitssex haben, sind einem erhöhten Risiko ausgesetzt, sich mit sexuell übertragbaren Infektionen, sogenannten Sexually Transmitted Infections (STIs), einschliesslich HIV, anzustecken. Ein Auslandaufenthalt, wobei man auch neue Menschen kennen lernt, kann damit verbunden sein, sich anders zu verhalten und mehr Risiken einzugehen, als man dies zu Hause tun würde. Es ist wichtig daran zu denken, dass ungeschützter Sex und mehrere neue Sexualpartner ein Risiko für Geschlechtskrankheiten darstellen. Geschlechtskrankheiten können unter Umständen schwere Komplikationen verursachen und zudem auf weitere Partner*innen übertragen werden, sofern diese nicht rechtzeitig bemerkt und behandelt werden. Sind Sie nicht sicher, ob es sich um eine Risikosituation handelt, dann hilft der 'Risk-Check' von Love Live weiter.
      Geschlechtskrankheiten sind Infektionen, die durch sexuellen Kontakt (vaginaler, analer oder oraler Sex) übertragen werden. Sie werden durch mehr als 30 verschiedene Bakterien, Viren oder Parasiten verursacht, die in oder auf Ihrem Körper vorkommen. Es ist auch möglich, dass gleichzeitig mehr als eine STI gleichzeitig übertragen wird. Einige bedeutendsten STIs sind HIV (Informationsblatt HIV-AIDS), Hepatitis B, das humane Papillomavirus (HPV), Herpes simplex (HSV), Syphilis, Chlamydien und Gonorrhö.
      Geschlechtskrankheiten treten weltweit auf und können jeden und jede treffen, unabhängig von Alter, Geschlecht oder auch der sexuellen Orientierung. STIs kommen in vielen Ländern mit schwächerem Gesundheitssystem häufiger vor.
      Geschlechtskrankheiten werden in der Regel durch ungeschützten vaginalen, oralen oder analen Geschlechtsverkehr übertragen. Sie können aber auch durch andere intime Kontakte weitergegeben werden, wie z. B. Herpes und HPV, die durch Hautkontakt/Küssen übertragen werden. Andere können auch auf nicht sexuellem Wege übertragen werden, z.B. über Blut. Viele Geschlechtskrankheiten - darunter Syphilis, Hepatitis B, HIV, Chlamydien, Tripper, Herpes und HPV - können auch während der Schwangerschaft und bei der Geburt von der Mutter auf das Kind übertragen werden.
      • Brennen oder Juckreiz im Genitalbereich
      • Schmerzhaftes oder häufiges Wasserlösen oder auch Schmerzen im Unterleib
      • Ungewöhnlicher Ausfluss aus dem Penis oder der Vagina
      • Wunden, Rötungen, Bläschen im Mund/Lippen oder Genitalbereich sowie Warzen im Intimbereich
      • Manchmal auch Fieber (eher selten)

      Wichtig: Eine STI kann auch ohne oder mit nur leichten Symptomen auftreten. Auch wenn Sie sich dessen nicht bewusst sind, können Sie andere anstecken. Deshalb ist es wichtig sich testen zu lassen.

      Geschlechtskrankheiten können bei einer körperlichen Untersuchung oder durch die Untersuchung von Urin, einer Wunde, eines Bläschens oder eines Abstrichs aus der Vagina, dem Penis oder dem Anus diagnostiziert werden. Bluttests können bei der Diagnose helfen. Auch wenn Sie keine Symptome haben, sollten Sie mit ihrer Ärztin, ihrem Arzt sprechen, wenn Sie im Ausland ungeschützten Geschlechtsverkehr hatten. Denn eine frühzeitige Erkennung und Behandlung ist wichtig, um eine Errergerübertragung und Komplikationen durch unbehandelte STIs zu verhindern.
      Viele Geschlechtskrankheiten sind heilbar, andere wie z.B. HIV jedoch nicht und bedeuten, dass lebenslang Medikamente eingenommen werden müssen, damit es nicht zu Komplikationen kommt. Beispielsweise können mit Antibiotika bakteriell verursachte STIs geheilt werden. Eine frühzeitige Behandlung verringert zudem das Risiko von Komplikationen. Denn unbehandelt können einige STIs langfristig unter Umständen zu Gesundheitsproblemen führen, wie z.B. zu Unfruchtbarkeit, Geburtskomplikationen und einigen Arten von Krebs. Wenn eine schwangere Frau eine STI hat, kann dies zu Gesundheitsproblemen beim Baby führen. Auch Sexualpartner sollten gleichzeitig behandelt werden, um eine erneute Infektion zu verhindern (Ping-Pong-Übertragung).
      • Beachten Sie die Safer Sex Regeln von Love Live. Dazu gehört auch bei jedem Anal- oder Vaginalverkehr Kondome zu verwenden.
      • Denken Sie daran, dass es bei Oralverkehr auch zu Übertragungen von STIs kommen kann.  
      • Lassen Sie sich impfen! Es gibt Impfstoffe zum Schutz vor HPV, Hepatitis A und Hepatitis B.
      • Hatten Sie eine Risikosituation, ist es wichtig mit einer Fachperson so rasch wie möglich Rücksprache zu halten, um zu erörtern, ob eine HIV-Post-Expositions-Prophylaxe (PEP) durchgeführt werden soll, um eine HIV-Infektion zu verhindern. Am wirksamsten ist eine HIV-PEP innerhalb weniger Stunden danach.
      • Es gibt auch weitere Präventionsmassnahmen für spezielle Situationen (Präexpositionsprophylaxe HIV-PrEP). Sprechen Sie mit einer damit erfahrenen Fachperson vor Abreise darüber.
      • Denken Sie daran, dass Alkohol oder Drogen zu erhöhtem Risikoverhalten führen.
      • Denken Sie daran, dass Sie eine weitere Person/bekannter Partner*in bei ungeschütztem Sex anstecken können, sofern bei Ihnen eine unbehandelte STI vorliegt.
      • Menschen mit einer neu diagnostizierten STI sind angehalten ihre früheren Sexualpartner*innen zu informieren, damit auch sie behandelt werden können.

      Durch Bakterien oder Parasiten hervorgerufen
      Alle diese Krankheiten können geheilt werden. Wichtig ist dabei, frühzeitig zu testen und umgehend zu therapieren, um Komplikationen und v.a. weitere Übertragungen zu vermeiden.

      • Syphilis
        Auch bekannt als Lues. Sie wird durch das Bakterium Treponema pallidum verursacht. Das erste Anzeichen ist eine schmerzlose Wunde an den Genitalien, im Mund, auf der Haut oder im Rektum, die hochgradig ansteckend ist und nach 3 bis 6 Wochen spontan abklingt. Da diese schmerzlos ist, nehmen nicht alle Patienten*innen diese Läsion wahr. Oft heilt diese Infektion jedoch nicht von selbst aus. In der zweiten Phase können Hautausschlag, Halsschmerzen und Muskelschmerzen auftreten. Unbehandelt kann die Krankheit im Verborgenen (latent) bleiben, ohne dass Symptome auftreten. Etwa ein Drittel der Infizierten mit unbehandelter Syphilis entwickelt im Verlauf Komplikationen. Diese Spätform wird als  sogenannt tertiäre Syphilis bezeichnet . In diesem Stadium kann die Krankheit alle Organe befallen: am häufigsten das Gehirn, die Nerven und die Augen. Die Infektion kann während der Schwangerschaft auf den Fötus und bei der Geburt auf das Kind übertragen werden.

      • Chlamydia trachomatis
        Chlamydien können ungewöhnlichen Ausfluss aus dem Penis oder der Vagina, Unbehagen beim Wasserlösen und Unterleibsschmerzen verursachen. Oft treten keine Symptome auf. Unbehandelt können sie zu Unfruchtbarkeit führen und die Krankheit kann auf Sexualpartner*innen übertragen werden. Die Bakterien können auch während der Schwangerschaft auf den Fötus, oder während der Geburt auf das Kind übertragen werden und Augeninfektionen oder Lungenentzündungen verursachen.

      • Gonorrhoe
        Auch bekannt als Tripper. Zu den häufigsten Symptomen gehören Ausfluss aus der Vagina oder dem Penis und schmerzhaftes Wasserlassen. Symptome müssen aber nicht immer auftreten. Sowohl bei Männern als auch bei Frauen kann Gonorrhoe auch den Mund, den Rachen, die Augen und den Anus infizieren und sich auf das Blut und die Gelenke ausbreiten, wo sie in eine schwere Krankheit übergehen kann. Bleibt sie unbehandelt, kann sie eine Beckenentzündung verursachen, die zu chronischen Beckenschmerzen und Unfruchtbarkeit führen kann. Die Krankheit kann während der Schwangerschaft auf den Fötus übertragen werden.

      • Weitere bakterielle STIs: Mykoplasmen und Ureaplasmen. Diese können ebenfalls behandelt werden.

      • Trichomoniasis
        Sie wird durch einen Parasiten verursacht, der mit einer einzigen Dosis eines Antibiotikums behandelt werden kann. Trichomoniasis kann bei Frauen einen übel riechenden Scheidenausfluss, Juckreiz im Genitalbereich und schmerzhaftes Wasserlassen verursachen. Bei Männern treten in der Regel weniger oder keine Symptome auf. Zu den Komplikationen gehört das Risiko einer vorzeitigen Entbindung bei schwangeren Frauen. Um eine Reinfektion zu verhindern, sollten beide Sexualpartner behandelt werden.

      Durch Viren hervorgerufen

      • HIV/AIDS - siehe Informationsblatt HIV-AIDS

      • Herpes simplex Virus
        Im Lippen-Mundbereich, auch bekannt als Fieberbläschen, ist nicht heilbar. Herpes kann aber mit Medikamenten bei akuten Beschwerden kontrolliert werden. Die Symptome sind in der Regel schmerzhafte, wässrige Hautbläschen und finden sich an oder um die Genitalien, den Anus oder den Mund. Nach der Erstinfektion ruht das Virus im Körper und die Symptome können über Jahre hinweg wieder auftreten. Schwangere Frauen können die Infektion an ihre Neugeborenen weitergeben, was zu einer bedrohlichen Infektion führen kann.

      • Virale Hepatitis (siehe auch Hepatitis Schweiz)
        • Hepatitis A (HAV)
          Hepatitis A ist eine durch Impfung vermeidbare Leberinfektion, die durch das Hepatitis-A-Virus verursacht wird. Das Hepatitis-A-Virus findet sich im Stuhl und im Blut infizierter Personen. Hepatitis A kann durch verunreinigtes Wasser und Lebensmittel sowie bei anal-oralen sexuellen Aktivitäten übertragen werden. Die Patienten*innen leiden an einer akuten und oft schweren Erkrankung, erholen sich aber allermeist spontan.
        • Hepatitis B (HBV)
          Das Hepatitis-B-Virus wird durch sexuelle Kontakte sowie durch den Kontakt mit anderen Körperflüssigkeiten, wie z.B. Blut, übertragen. Zur Übertragung kann es z.B. auch bei medizinischen Eingriffen oder Brennen eines Tatoos unter nicht optimalen hygienischen Bedingungen kommen. Hepatitis B kann eine schwere Leberinfektion verursachen, die sowohl zu einer sofortigen Erkrankung, als auch zu einer lebenslang andauernden Infektion führen kann mit möglicher Folge einer dauerhaften Lebervernarbung (Zirrhose) und Krebs. Schwangere Frauen mit Hepatitis B können das Virus während der Geburt auf ihr Kind übertragen. Zu Beginn der Infektion haben Sie möglicherweise keine Symptome.  Das Virus kann auf Sexualpartner*innen übertragen werden. Hepatitis B kann mit antiviralen Medikamenten behandelt werden, ist aber nur selten heilbar. Eine Impfung kann eine Hepatitis-B-Infektion verhindern.
        • Hepatitis C (HCV)
          In den meisten Fällen wird Hepatitis C durch den Kontakt mit infiziertem Blut übertragen. Seltener kann es durch analen Sexualkontakt oder von der Mutter auf das Kind während der Schwangerschaft und Geburt übertragen werden. Die meisten Infizierten sind sich ihrer Infektion nicht bewusst, weil sie keine Symptome entwickeln, aber diese chronische Infektion kann zu Leberzirrhose und Krebs führen. Hepatitis C kann behandelt werden, eine Impfung gibt es nicht.

      • Humanes Papillomavirus (HPV)
        HPV ist die häufigste Geschlechtskrankheit. Es gibt eine Vielzahl verschiedener HPV-Typen, und einige von ihnen können Genital-, Anal- und Mundwarzen sowie Gebärmutterhals-, Penis- oder Rachenkrebs verursachen. Die Symptome können auch noch Jahre nach dem Sex mit einer infizierten Person auftreten. Zwei verfügbare Impfstoffe schützen gegen die wichtigsten HPV-Typen, die Gebärmutterhals-, Penis- oder Analkrebs verursachen.

      • Zika - siehe Informationsblatt Zika
        In den meisten Fällen wird es vor allem durch Stechmücken übertragen. Es kann aber auch sexuell übertragen werden. Eine Ansteckung mit Zika während der Schwangerschaft kann bei dem sich entwickelnden Fötus Geburtsfehler wie Mikrozephalie (kleiner Kopf mit neurologischen Ausfällen) verursachen. Die einzige Möglichkeit, eine sexuelle Übertragung des Virus während der Schwangerschaft zu verhindern, besteht darin, Vorsichtsmassnahmen (Kondome) zu treffen oder Sex (mindestens 2 Monate nach der Rückkehr) mit jemandem zu vermeiden, der kürzlich in ein Risikogebiet gereist ist, auch wenn der Reisende keine Symptome hat.
      • Love Life: www.lovelife.ch 
      • Sexuelle Gesundheit Schweiz: www.sexuelle-gesundheit.ch 
      • Hepatitis Schweiz: https://hepatitis-schweiz.ch/formen/was-ist-hepatitis 
      • World Health Organization (WHO). Factsheets. Sexually transmitted infections (STIs). 14 June 2019: www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis) 
      • Centers for Disease Control and Prevention (CDC). Factsheet: Information for Teens and Young Adults: Staying Healthy and Preventing STDs (2017): www.cdc.gov/std/life-stages-populations/stdfact-teens.htm 
      • Centers for Disease Control and Prevention (CDC). How You Can Prevent Sexually Transmitted Diseases: www.cdc.gov/std/prevention/ 
      • Centers for Disease Control and Prevention (CDC) Sexual Transmission and Prevention. Zika Virus: www.cdc.gov/zika/prevention/protect-yourself-during-sex.html 
      • Centers for Disease Control and Prevention (CDC) Zika and Pregnancy; Pregnant Women and Zika (March 2021): www.cdc.gov/pregnancy/zika/protect-yourself.html 
      Countrywide
       
       
      • Schistosomes are parasitic worms that infect humans while bathing or walking in fresh water ponds, lakes, or slow-flowing rivers.
      • Avoid bathing, washing, or walking in fresh water in areas endemic for schistosomiasis, also called bilharzia.
      • Consult a general practitioner or a specialist in travel and tropical medicine after suspected skin contact with fresh water during a trip.
      • Specific diagnostic tests and an effective treatment are available, which can prevent long-term complications.

      EKRM_Factsheet_Layperson_EN_Schistosomiasis.pdf

      WHO Map: Schistosomiasis, countries or areas at risk, 2014
      • Schistosomes are parasitic worms that infect humans while bathing or walking in fresh water ponds, lakes, or slow-flowing rivers.
      • Avoid bathing, washing, or walking in fresh water in areas endemic for schistosomiasis, also called bilharzia.
      • Consult a general practitioner or a specialist in travel and tropical medicine after suspected skin contact with fresh water during a trip.
      • Specific diagnostic tests and an effective treatment are available, which can prevent long-term complications.
      Schistosomes are parasitic worms that infect humans while bathing or walking in fresh water ponds, lakes, or slow-flowing rivers. The larvae of the worm penetrate the skin and migrate in the body until they settle as adults in the veins surrounding the intestines or the genital and urinary tracts, depending on the parasite type. Chronic complications are due to the worms’ eggs, which trigger inflammation and fibrosis (scar tissue) in affected organs.
      Schistosomiasis occurs in Sub-Saharan Africa and the Arabian Peninsula, Asia (China, the Philippines, South-East Asia), north-eastern South America, and some Caribbean islands.
      The larvae of schistosomes are shed by fresh water snails and penetrate the skin of humans when they bath or swim in the water. The worms develop in various organs of the human body, producing eggs that later migrate through the walls of the intestines and the urinary bladder where they trigger an inflammation and can impair the function of the respective organ systems over the course of months or years. The eggs are deposited in fresh water bodies when humans defecate or urinate into them. Larvae hatch from these eggs and infect water snails, thus completing the parasitic cycle.
      Many infections do not cause any signs or symptoms. These depend on the stage of infection: soon after the larvae penetrate the human skin in fresh water, an itching rash may appear (‘swimmer’s itch’). An immunological reaction after 4-8 weeks sometimes occurs with fever and feeling sick, the so-called ‘Katayama fever’. Chronic symptoms such as bloody urine, pain in passing urine, (bloody) diarrhea, and abdominal pain eventually occur after months or years. If those symptoms occur and treatment is not given, damage to the urinary and gastrointestinal tract can lead to dysfunction of the organs.
      Consult a tropical disease specialist for diagnosis and management. Specific drugs are effective and prescribed when eggs are detected in the urine or stool, or when the blood test shows antibodies against the worms (see below).
      Avoid bathing, washing, or walking in fresh water ponds or slow-flowing rivers in endemic areas. Correctly treated swimming pools and sea water are safe! There is not enough evidence for post-exposure treatment.
      If any suspicious fresh water contacts occurs during a trip, a tropical medicine specialist or general practitioner should be consulted for a blood test, approximately 2 months after exposure.
      Areas above 2500 meters
       
       
       
      • Altitude sickness can be life-threatening and may be experienced by any traveler.
      • The danger begins at around 2500m and rises with increasing altitude.
      • People differ in their susceptibility to altitude sickness; this is not related to their physical fitness.
      • Severe altitude sickness with fluid accumulation in the brain or lungs can rapidly result in death.
      • If you are planning a stay in high altitudes, we strongly recommend you to consult your doctor for detailed recommendations and instructions.

      20230227_Factsheet_Layperson_EN_Altitude-sickness.pdf

      • Eine Höhenkrankheit kann lebensgefährlich sein und bei jedem Reisenden auftreten.
      • Die Gefahr beginnt bei ca. 2500m und nimmt mit zunehmender Höhe zu.
      • Wenn Sie einen Höhenaufenthalt planen, lesen sie bitte dieses Merkblatt aufmerksam durch!
      • Je nach Reiseart und / oder Vorerkrankungen wird die Beratung durch eine Fachperson dringend angeraten.
      Reisen in die Anden, den Himalaya oder Ostafrika (z.B. Kilimanjaro) können in ungewohnte Höhen führen. In vielen Reiseangeboten werden für diese Höhentreks nur wenige Tage vorgesehen, was eine ungewöhnliche Anforderung und zum Teil eine Überforderung für den Organismus bedeutet. Reisen in grosse Höhen sind nicht risikolos, auch nicht für gesund befundene Personen. Personen, die schon zu Hause an Atem- oder Herzbeschwerden leiden, sollten sich bei ihrem Hausarzt beraten lassen.
      Die Gefahr einer akuten Bergkrankheit besteht bei allen Personen. Das Risiko eine akute Bergkrankheit zu erleiden, ist weitestgehend unabhängig von Alter und Trainingszustand und wird in erster Linie von der Aufstiegsgeschwindigkeit und der Schlafhöhe bestimmt. Die Gefahr beginnt ungefähr bei 2500m und nimmt mit zunehmender Höhe zu. Die akute Höhenkrankheit äussert sind durch Kopfschmerzen, Übelkeit, Appetitverlust und Schlafstörungen.
      Nehmen die obigen Symptome zu, z.B. keine Reaktion der Kopfschmerzen mehr auf Kopfwehtabletten, und werden zusätzlich von Schwindel, Erbrechen, Teilnahmslosigkeit, Gangunsicherheit und ev. Atemnot begleitet, dann soll schnellstmöglich abgestiegen werden bzw. der Erkrankte in tiefere Lagen abtransportiert werden. Beim Nichtabsteigen besteht die Gefahr, dass es zu lebensbedrohlichen Zuständen wie Höhenhirnödem und/oder Höhenlungenödem kommt.
      1. Langsamer Aufstieg. Aufstiegsregeln: oberhalb von 2500m sollte die Schlafhöhe um nicht mehr als 300-500m pro Tag gesteigert werden und pro 1000m Schlafhöhengewinn sollte ein zusätzlicher Ruhetag eingelegt werden.
      2. Treten Beschwerden auf, die auf eine Bergkrankheit hinweisen (siehe oben), muss der Anstieg pausiert werden und er darf erst wieder bei Beschwerdefreiheit fortgesetzt werden. Bei Zunahme der Beschwerden muss abgestiegen werden bzw. Patient:innen in tiefere Lagen abtransportiert werden. Bei Ignorieren zunehmender Beschwerden können sich die lebensbedrohlichen Formen der Höhenkrankheit, das Höhenhirnödem und/oder das Höhenlungenödem entwickeln.
      3. Ist das Einhalten der oben genannten Aufstiegsregeln situativ oder geländebedingt nicht möglich, kann die Einnahme von Acetazolamid (DIAMOX®) das Risiko eine akute Höhenkrankheit zu entwickeln, vermindern. Die Verschreibung des Medikaments bedingt eine ärztliche Indikationsstellung sowie eine Aufklärung über allfällige Nebenwirkungen!
      • Kopfschmerzen: Paracetamol (z.B. PANADOL®, DAFALGAN®). Keine Schlafmittel verwenden!
      • Höhenhirnödem: sofortiger Abstieg. Falls verfügbar: Sauerstoffgabe, medikamentöse Notfalltherapie.
      • Höhenlungenödem (Atemnot auch in Ruhe, rasselndes Atemgeräusch, Reizhusten) Sofortiger Abstieg. Falls verfügbar: Sauerstoffgabe, medikamentöse Notfalltherapie.
       
       
      • Dengue fever is the world's most common insect-borne infectious disease.
      • Great attention should be paid to mosquito protection during the day!
      • The disease can cause high fever, muscle and joint pain, and skin rashes. In rare cases, bleeding may occur.
      • There is no specific treatment. Vaccination is recommended only for people with evidence of previous dengue infection.
      • For personal safety, we strongly recommend that you inform yourself in detail about dengue.

      EKRM_Factsheet_Layperson_EN_Dengue.pdf

      EKRM_Factsheet_Layperson_EN_Mosquito-and-tick-bite-protection.pdf

      ECTM_Dengue_Vaccination_Statement_EN_Publication_Sept_2024.pdf

       
       
      • Marburg virus disease is a rare but severe hemorrhagic fever.
      • The disease spreads through contact with infected animals or people.
      • Symptoms can be similar to other tropical diseases
      • There is no licensed treatment or vaccine for Marburg disease, and
      • Please have a look to the factsheet below.

      EKRM_Factsheet_Layperson_EN_MARBURG.pdf

      CDC Map: History of Marburg Outbreaks Marburg, Link CDC
      • Marburg virus disease is a rare but severe hemorrhagic fever.
      • The disease spreads through contact with infected animals or people.
      • Symptoms can be similar to other tropical diseases
      • There is no licensed treatment or vaccine for Marburg disease, and
      • Prevention measures are important to follow, see below.
      Marburg virus disease (MVD) is a rare but severe hemorrhagic fever, caused by Marburg virus (MARV). Although MVD is uncommon, it has the potential to cause epidemics with significant case fatality rates (50 to 88%).
      All recorded MVD outbreaks have originated in Africa. Fruit bats are the natural reservoirs for Marburg virus. Caves or mines colonized with bats are an important source of infection.
      The majority of MVD outbreaks have been connected to human entry into bat-infested mines and caves. Transmission occurs by direct contact (through broken skin or mucous membranes) with blood, secretions, and body fluids of an infected animal or human or by indirect contact with contaminated surfaces and materials like clothing, bedding and medical equipment (for instance in healthcare settings). MVD is not an airborne disease, and a person is not contagious before symptoms appear. As a result, if proper infection prevention and control precautions are strictly followed, the risk of infection is regarded as minimal.

      The incubation period (time between infection and onset of symptoms) ranges from a 2 to 21 days (usually 5 to 10 days). The onset of MVD is usually abrupt, with initially non-specific, flu-like symptoms such as a high fever, severe headache, chills and malaise. Rapid worsening occurs within 2–5 days for more than half of patients, marked by gastrointestinal symptoms such as anorexia, abdominal discomfort, severe nausea, vomiting, and diarrhoea. As the disease advances, clinical manifestations can become more severe and include liver failure, delirium, shock, bleeding (hemorrhaging), multi-organ dysfunction and death.

       

      In case of symptoms

      If think that you have had an exposure at risk and develop fever with nonspecific symptoms such as chills, headache, muscle pain, malaise or abdominal pain:

      • you should separate yourself from others (isolate) immediately and
      • immediately seek medical advice by contacting the in-country hotline by phone or contact a tropical institute or university hospital infectious disease unit.
      • alert the healthcare providers of your recent travel to an area with a Marburg outbreak.
      Currently, there are no licensed treatments for Marburg disease. Treatment is limited to supportive care (rest, hydration, managing oxygen status and blood pressure, treatment of secondary infections). Without supportive care, high proportion of infected people die.

      The risk for travellers is  very low if the below precautions are followed, but it is high for family members and caregivers who have contact with sick people.

       

      General precautions during travel to affected areas:

      • Wash your hands regularly and carefully using soap and water (or alcohol gel if soap is unavailable).
      • Avoid contact with sick people who have symptoms, such as fever, muscle pain, and rash.
      • Avoid contact with blood and other body fluids
      • Avoid visiting healthcare facilities in the MVD-affected areas for nonurgent medical care or non-medical reasons.
      • Avoid contact with dead bodies or items that have been in contact with dead bodies, participating in funeral or burial rituals, or attending a funeral or burial. 
      • Avoid handling, cooking, or eating bush/wild meat (meat of wild/feral mammals killed for food).
      • Wash and peel fruit and vegetables before consumption.
      • Avoid visiting mines or bat caves and contact with all wild animals; alive or dead, particularly bats.
      • If you decide to visit mines or caves inhabited by fruit bat colonies, wear gloves and other appropriate protective clothing, including masks and eye protection.
      • Practice safer sex.
      • Swiss Federal Office of Public Health: LINK
      • European Center for Disease Control and Prevention (ECDC): Marburg virus disease
      • US Center for Disease Control and Prevention (CDC): About Marburg Disease
      • World Health Organization: Marburg Virus Disease
      Woldwide
       
       
      • Mpox is a viral disease that typically causes a rash, swollen lymph nodes and fever.
      • An emerging variant is spreading rapidly in eastern D.R. Congo and neighbouring countries, leading the WHO to declare a new Public Health Emergency International (PHEIC) in August 2024.
      • Close physical contact (sexual or non-sexual) is the main route of transmission.
      • The disease is usually mild. Children, pregnant women and people with weakened immune systems are most at risk of complications.
      • Take general precautions (see factsheet) to prevent the disease.
      • There is a vaccination against Mpox, but it is currently only available for people at high risk.

      EKRM_Factsheet_Layperson_MPOX_EN.pdf

      WHO Map: 2025 Monkeypox Outbreak Global Map
      • Mpox is a viral disease that typically causes a rash, swollen lymph nodes and fever.
      • An emerging variant is spreading rapidly in eastern D.R. Congo and neighboring countries prompting a new WHO declaration of a public health emergency of international concern (PHEIC), as of August 14th 2024.
      • Close physical contact (sexual or non-sexual) is the main mode of transmission.
      • The disease generally follows a mild course. Children, pregnant women, and people with weak immune systems are the most at risk of complications.
      • Vaccination against mpox is available, but limited to groups at high risk of exposure. 
      Mpox (formerly monkeypox) is a disease caused by the Monkeypox virus, a virus from the same family as the virus that causes smallpox. It is a viral zoonotic disease, which means it can spread from animals to humans. It can also spread between people.

      Mpox has been commonly found in West and Central Africa for many years where the suspected reservoir - small mammals - is endemic. There are two types of Monkeypox virus called ‘clades’ that cause the disease mpox - clade I in Central Africa and clade II in West Africa. Since the end of smallpox vaccination campaigns in the early 1980’s, cases of mpox have increased, slowly at first and significantly in the last 5-10 years, especially in the Democratic Republic of Congo (DRC).

       

      In 2022, a new emerging subclade of clade II was responsible for a global epidemic that spread mainly through sexual contact among men who have sex with men. It resulted in the first public health emergency of international concern (PHEIC) declared by the WHO until 2023. Although the clade II epidemic is now under control, this virus variant continues to circulate worldwide.


      In 2024, the continued spread of mpox clade I in endemic regions of Central Africa, particularly in the DRC, and the emergence of a new subclade Ib in Eastern DRC and neighboring countries have raised global concern and prompted the WHO to declare a PHEIC for the second time in two years. The current geographical spread of the mpox clade Ib variant occurs via commercial routes through sexual contact (e.g. sex workers), followed by local transmission in households and other settings (which is becoming increasingly important).

      Animal to human transmission
      Mpox can spread from animal to human when they come into direct contact with an infected animal (rodents or primates).

       

      Human to human transmission
      Mpox can be spread from person to person through close physical contact (sexual and non-sexual contact) with someone who has symptoms of mpox. Skin and mucous membrane lesions, body fluids, and scabs are particularly infectious. A person can also become infected by touching or handling clothing, bedding, towels, or objects such as eating utensils/dishes that have been contaminated by contact with a person with symptoms. Household members, family caretakers, and sexual partners of a confirmed case of mpox are at higher risk for infection as are health care workers who treat a case without adequate personal protection.

      The incubation period (time between infection and onset of symptoms) ranges from a few days up to 3 weeks. Mpox causes a rash / skin eruption that can be painful associated with swollen lymph nodes and fever. Fever may start already before the rash phase. Other symptoms include muscle aches, back pain, and fatigue. The rash may be localized or generalized, with few or hundreds of skin lesions. It mainly affects the face, the trunk and the palms of hand and soles of the feet. It can also be present in genital areas and on mucous membranes such as in the mouth and throat. Symptoms usually last 2 to 4 weeks and the person remains contagious until all lesions have healed (once the cabs have fallen off).

      Complications include secondary bacterial infections, infections of the lung and brain and involvement of other organs, still birth and others. Children, pregnant women, and people with weak immune systems are at higher risk to develop a severe form of mpox.

      The majority of person with mpox recovers spontaneously and do not need specific antiviral treatment. Care management consists of relieving pain and other symptoms and preventing complications (e.g., superinfection). Several antiviral treatments are studied in various countries and may be used in trials or in clinical situations according to the recommendations of national medical societies.

       

      In case of symptoms: 

      • Seek medical attention immediately
      • If you are diagnosed with mpox
        • Please stay at home (isolate yourself) until your mpox rash has healed and a new layer of skin has formed. Staying away from other people and not sharing things you have touched with others will help prevent the spread of mpox. People with mpox should regularly clean and disinfect the spaces they use to limit household contamination.
        • Wash your hands often with soap and water or an alcohol-based hand sanitiser containing at least 60% alcohol.
        • You should not have sex while symptomatic and while you have lesions or symptoms. Use condoms for 12 weeks after infection. This is a precaution to reduce the risk of spreading the virus to a partner.
        • For more information on what do if you are sick, see CDC LINK.

      General precautions:

      • Worldwide:
        • avoid close, skin-to-skin contact with people who have or may have mpox or people who have a rash (e.g., pimples, blisters, scabs).
        • Wash your hands often with soap and water or an alcohol-based hand sanitiser containing at least 60% alcohol.
        • Avoid touching potentially contaminated personal items such as cups, bedding/clothing, towels or sharing eating utensils/cups, food or drink with a person who has, or may have mpox.
        • Avoid sex with sick persons; use of condoms for up to 12 weeks if you sexual partner have had mpox.
        • Follow advice of local authorities.
      • When travelling to endemic / epidemic areas in Africa, in addition to above mentioned general precautions: 
        • Avoid contact with and animals in areas where mpox regularly occurs.
        • Avoid eating or preparing meat from wild animals (bushmeat) or using products (creams, lotions, powders) derived from wild animals.

      Vaccination:

      There are several vaccines against mpox (e.g. Jynneos®, manufacture Bavarian Nordic). The Bavarian Nordic vaccine was originally developed to fight against smallpox, but offers a cross-protection against mpox. In Switzerland, the Jynneos® vaccine has been licensed by Swissmedic since 2024. Groups at risk (e.g., men who have sex with men or transgender people with multiple sex partners) are eligible for vaccination since 2022 and this recommendation remains unchanged (see FOPH recommendations). In light of the epidemiological situation in Africa in 2024, the Swiss Expert Committee for Travel Medicine recommends vaccination against mpox for professionals who are / will be in contact with suspect mpox patients or animals in endemic/epidemic regions or who work in a laboratory with the virus (for updates, see news).

      The risk to the general population and travelers (tourists) is considered extremely low if the above-mentioned general precautions are followed and vaccination is not recommended.

      • Seek medical attention immediately.
      • Mpox is not a sexual transmitted disease in the strict sense, physical contact with a person with symptoms of mpox (rash at any stage) is sufficient to transmit the disease. Condoms do not protect you from getting mpox!
      • Swiss Federal Office of Public Health (FOPH)                                                            
      • World Health Organisation: WHO FAQ
      • European Center of Disease Control and Prevention (ECDC)
      • US Center of Disease Control and Prevention (CDC)
        
       
       
       

      There is a risk of arthropod-borne diseases other than malaria, dengue, chikungunya or zika in sub-/tropical regions, and some areas of Southern Europe. These include the following diseases [and their vectors]:

      • in Europe
        • Borreliosis, FSME (= tick-borne encephalitis), rickettsiosis [ticks]
        • Leishmaniasis [sand flies]
        • West-Nile fever [mosquitoes]
      • in Africa
        • Rickettsiosis, in particular African tick bite fever [ticks]
        • Leishmaniasis [sand flies]
        • African trypanosomiasis = sleeping sickness [tsetse flies]
        • West-Nile fever [mosquitoes]
      • in Asia 
        • Scrub typhus [mites]
        • Rickettsiosis [fleas or ticks]
        • Leishmaniasis [sand flies]
        • West-Nile fever [mosquitoes]
        • Crimea-Congo-hemorrhagic fever [ticks]
      • in North and Latin America  
        • Rickettsioses and in particular Rocky Mountain spotted fever [ticks]
        • Leishmaniasis and Carrion's disease [sand flies]
        • American trypanosomiasis = Chagas disease [triatomine bugs]
        • West Nile fever [mosquitoes]
      Under construction
       
        
       
       
       
      • There are other important travel related health risks such as diarrhoea, road traffic accidents, air pollution and more.
      • For more information, see the section "Healthy Travelling".

      Get in touch with us

      • Sekretariat Schweizerische Fachgesellschaft für Tropen- und Reisemedizin,
        Socinstrasse 55, Postfach, 4002 Basel

      • info@healthytravel.ch
      • Ask a specialist
      • News
      • Contact
      • Payment Plans
      • Sponsors
      • Legal notice

      Copyright © 2025. All Rights Reserved

      0

      Bookmarks